NCT02971605View on ClinicalTrials.gov

Persisting Effects of Psilocybin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

August 21, 2018

Study Completion Date

August 21, 2018

Conditions
Healthy
Interventions
DRUG

Psilocybin

25 mg/70 kg Psilocybin

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT02971605 - Persisting Effects of Psilocybin | Biotech Hunter | Biotech Hunter